NO20082389L - 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler - Google Patents
2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidlerInfo
- Publication number
- NO20082389L NO20082389L NO20082389A NO20082389A NO20082389L NO 20082389 L NO20082389 L NO 20082389L NO 20082389 A NO20082389 A NO 20082389A NO 20082389 A NO20082389 A NO 20082389A NO 20082389 L NO20082389 L NO 20082389L
- Authority
- NO
- Norway
- Prior art keywords
- triphenylimidazoline
- inhibitors
- derivatives
- interaction
- anticancer agents
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- -1 2,3,4-triphenylimidazoline derivatives Chemical class 0.000 title 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74122305P | 2005-12-01 | 2005-12-01 | |
| US85274706P | 2006-10-19 | 2006-10-19 | |
| PCT/EP2006/068748 WO2007063013A1 (en) | 2005-12-01 | 2006-11-22 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082389L true NO20082389L (no) | 2008-08-18 |
Family
ID=37866229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082389A NO20082389L (no) | 2005-12-01 | 2008-05-26 | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7851626B2 (pt) |
| EP (3) | EP1960368B1 (pt) |
| JP (1) | JP4870778B2 (pt) |
| KR (2) | KR20100129331A (pt) |
| CN (1) | CN101316823B (pt) |
| AR (1) | AR057990A1 (pt) |
| AU (1) | AU2006319248B2 (pt) |
| BR (1) | BRPI0619236A2 (pt) |
| CA (1) | CA2630410C (pt) |
| CR (1) | CR9980A (pt) |
| ES (1) | ES2538714T3 (pt) |
| MA (1) | MA31550B1 (pt) |
| NO (1) | NO20082389L (pt) |
| NZ (1) | NZ568285A (pt) |
| RU (1) | RU2442779C2 (pt) |
| TW (1) | TWI326681B (pt) |
| WO (1) | WO2007063013A1 (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007312390B2 (en) * | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
| JP5079011B2 (ja) * | 2006-10-19 | 2012-11-21 | エフ．ホフマン−ラ ロシュ アーゲー | 糖尿病のための１１β−ＨＳＤ１阻害剤としてのイミダゾロン及びイミダゾリジノン誘導体 |
| EP2176216B1 (en) * | 2007-07-06 | 2012-04-25 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing 9-substituted minocycline |
| MX2010003868A (es) * | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| PT2380892E (pt) | 2009-01-16 | 2014-06-09 | Daiichi Sankyo Co Ltd | Derivado de imidazotiazole compreendendo uma estrutura de anel prolina |
| WO2011023677A1 (en) * | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| EP2621275B1 (en) * | 2010-09-30 | 2018-03-28 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| MX2013006739A (es) | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| EP2771008A4 (en) | 2011-10-28 | 2015-04-08 | Merck Sharp & Dohme | MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| TWI654180B (zh) | 2012-06-29 | 2019-03-21 | 美商艾佛艾姆希公司 | 殺真菌之雜環羧醯胺 |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| CN103012272B (zh) * | 2012-12-21 | 2015-01-28 | 江苏国泰超威新材料有限公司 | 一种咪唑啉化合物的制备方法 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112015031542A2 (pt) * | 2013-07-03 | 2017-07-25 | Hoffmann La Roche | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| ES2712973T3 (es) | 2014-04-17 | 2019-05-17 | Univ Michigan Regents | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos |
| EP3242875B1 (en) * | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| SG11201911909UA (en) * | 2017-06-16 | 2020-01-30 | Unity Biotechnology Inc | Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use |
| CA3096978A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| KR102039696B1 (ko) | 2018-04-23 | 2019-11-04 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 |
| CN114075121B (zh) * | 2020-08-19 | 2025-08-29 | 中国科学院上海有机化学研究所 | 一类偶氮化合物的制备方法及其用途 |
| KR102622992B1 (ko) | 2021-03-29 | 2024-01-10 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 및 이의 중간체 제조방법 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
| RU2157368C2 (ru) * | 1994-09-26 | 2000-10-10 | Сионоги Энд Ко., Лтд. | Производные имидазола и фармацевтическая композиция на их основе |
| GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
| BR0215157A (pt) | 2001-12-18 | 2004-10-19 | Hoffmann La Roche | Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores |
| BR0215156A (pt) | 2001-12-18 | 2004-10-19 | Hoffmann La Roche | Cis-imidazolinas como inibidores de mdm 2 |
| US6878735B2 (en) * | 2002-05-31 | 2005-04-12 | Board Of Trustees Of Michigan State University | Multi-substituted imidazolines and method of use thereof |
| US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| AU2004254187A1 (en) * | 2003-06-17 | 2005-01-13 | F. Hoffmann-La Roche Ag | Cis-2,4,5-triaryl-imidazolines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| CN100562316C (zh) * | 2003-06-17 | 2009-11-25 | 霍夫曼-拉罗奇有限公司 | 作为mdm2抑制剂的顺式咪唑啉 |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| BRPI0511328A (pt) * | 2004-05-18 | 2007-12-04 | Hoffmann La Roche | cis-imidazolinas |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-11-22 CN CN2006800448100A patent/CN101316823B/zh not_active Expired - Fee Related
- 2006-11-22 KR KR1020107024025A patent/KR20100129331A/ko not_active Ceased
- 2006-11-22 ES ES06819663.3T patent/ES2538714T3/es active Active
- 2006-11-22 BR BRPI0619236-0A patent/BRPI0619236A2/pt not_active Application Discontinuation
- 2006-11-22 JP JP2008542723A patent/JP4870778B2/ja not_active Expired - Fee Related
- 2006-11-22 WO PCT/EP2006/068748 patent/WO2007063013A1/en not_active Ceased
- 2006-11-22 AU AU2006319248A patent/AU2006319248B2/en not_active Ceased
- 2006-11-22 RU RU2008126383/04A patent/RU2442779C2/ru active
- 2006-11-22 KR KR1020087013226A patent/KR101109437B1/ko not_active Expired - Fee Related
- 2006-11-22 CA CA2630410A patent/CA2630410C/en not_active Expired - Fee Related
- 2006-11-22 EP EP20060819663 patent/EP1960368B1/en active Active
- 2006-11-22 EP EP10175570A patent/EP2311814A1/en not_active Withdrawn
- 2006-11-22 NZ NZ568285A patent/NZ568285A/en not_active IP Right Cessation
- 2006-11-22 EP EP09166803A patent/EP2130822A1/en not_active Withdrawn
- 2006-11-27 US US11/604,558 patent/US7851626B2/en not_active Expired - Fee Related
- 2006-11-29 TW TW095144209A patent/TWI326681B/zh not_active IP Right Cessation
- 2006-11-29 AR ARP060105272A patent/AR057990A1/es not_active Application Discontinuation
-
2008
- 2008-05-16 CR CR9980A patent/CR9980A/es not_active Application Discontinuation
- 2008-05-26 NO NO20082389A patent/NO20082389L/no not_active Application Discontinuation
- 2008-06-02 MA MA30992A patent/MA31550B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2630410C (en) | 2014-02-25 |
| HK1126216A1 (en) | 2009-08-28 |
| TWI326681B (en) | 2010-07-01 |
| EP1960368B1 (en) | 2015-05-06 |
| EP2130822A1 (en) | 2009-12-09 |
| WO2007063013A1 (en) | 2007-06-07 |
| KR101109437B1 (ko) | 2012-01-31 |
| BRPI0619236A2 (pt) | 2011-09-20 |
| RU2442779C2 (ru) | 2012-02-20 |
| ES2538714T3 (es) | 2015-06-23 |
| CN101316823B (zh) | 2013-05-22 |
| AU2006319248B2 (en) | 2012-09-27 |
| EP1960368A1 (en) | 2008-08-27 |
| JP2009517439A (ja) | 2009-04-30 |
| TW200804297A (en) | 2008-01-16 |
| US20070129416A1 (en) | 2007-06-07 |
| CA2630410A1 (en) | 2007-06-07 |
| KR20100129331A (ko) | 2010-12-08 |
| RU2008126383A (ru) | 2010-01-10 |
| US7851626B2 (en) | 2010-12-14 |
| MA31550B1 (fr) | 2010-08-02 |
| JP4870778B2 (ja) | 2012-02-08 |
| EP2311814A1 (en) | 2011-04-20 |
| AU2006319248A1 (en) | 2007-06-07 |
| NZ568285A (en) | 2011-08-26 |
| CR9980A (es) | 2008-06-18 |
| KR20080072894A (ko) | 2008-08-07 |
| CN101316823A (zh) | 2008-12-03 |
| AR057990A1 (es) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
| JO2646B1 (en) | New differentiated cyclic compounds as beta - lactam inhibitors | |
| NO20054852L (no) | GFAT inhibitorer | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| NO20064077L (no) | Kemokinreseptorantagonister | |
| MX2011012628A (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. | |
| NO20070458L (no) | Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer | |
| MX2010005299A (es) | Derivados de bis-(sulfonilamino) en terapia 066. | |
| ATE519764T1 (de) | Spiroindolinon-derivate | |
| ATE389635T1 (de) | Pharmazeutisch wirksame piperidinderivate | |
| NO20065503L (no) | Indolyderivater som lever-X-resptormodulatorer. | |
| WO2007084728A3 (en) | 2-imino-benzimidazoles | |
| TW200626598A (en) | Pyrrazolo-pyrimidine derivatives | |
| NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
| MX2009007954A (es) | Derivado de heterocicliden-n-(aril) acetamida. | |
| WO2007120839A3 (en) | C-nitroso-derived nitroxyl donors | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
| NO20052074L (no) | Substituerte benzoksazinoner og anvendelser derav. | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| NO20052182L (no) | Nye forbindelser | |
| NO20064351L (no) | Caspaseinhibitorer og anvendelser derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |